Cardio Pulmonary Articles & Analysis

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square. During the presentation Mr. Athenson will discuss Third Pole’s strategy for its ...

By Third Pole Therapeutics, Inc.

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems as follows: US Patent No. 10,286.176 issued on May 14, 2019 titled ...

By Third Pole Therapeutics, Inc.

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Details of the events and presentation are as ...

By Third Pole Therapeutics, Inc.

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today. David Zapol, Third Pole’s founding CEO, will continue providing strategic counsel to Third Pole. Athenson joins Third Pole building on the ...

By Third Pole Therapeutics, Inc.

Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...

By Helioscopie SA

eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...

By Third Pole Therapeutics, Inc.

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are thrilled to receive this investment, which raises Third Pole Therapeutics’ series B financing and commitments to date to over $85M. I am ...

By Third Pole Therapeutics, Inc.

Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson. The collaboration will bring the global resources and know-how of the largest and most respected healthcare ...

By Third Pole Therapeutics, Inc.

Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies. The company plans to continue growing its team to power the expansion of Juvena’s ...

By Juvena Therapeutics, inc.